These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 14579493)

  • 21. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon beta and multiple sclerosis: look at the evidence.
    Patti F; Reggio A
    Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.
    Webb UH
    J Neurosci Nurs; 2008 Dec; 40(6):356-61. PubMed ID: 19170303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.
    Goodkin DE
    West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
    Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
    Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease-modifying therapy in relapsing--remitting multiple sclerosis: efficacy is paramount.
    Cristiano E
    Int J Clin Pract Suppl; 2002 Sep; (131):3-7. PubMed ID: 12564806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of multiple sclerosis in children and adolescents.
    Tenembaum SN
    Clin Neurol Neurosurg; 2010 Sep; 112(7):633-40. PubMed ID: 20471159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
    Neuhaus O; Stüve O; Archelos JJ; Hartung HP
    J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-beta1b for multiple sclerosis.
    Burks J
    Expert Rev Neurother; 2005 Mar; 5(2):153-64. PubMed ID: 15853486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glatiramer acetate (Copaxone).
    Francis DA
    Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of autoimmune attack and disease progression in multiple sclerosis: current therapies and future prospects.
    Pender MP; Wolfe NP
    Intern Med J; 2002 Nov; 32(11):554-63. PubMed ID: 12412939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ
    Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    Acta Neurol Scand; 2006 May; 113(5):283-7. PubMed ID: 16629762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current therapy of multiple sclerosis].
    Vass K; Schmied M
    Wien Med Wochenschr; 1996; 146(19-20):514-9. PubMed ID: 9082651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.